Background {#Sec1}
==========

With the gradual aging of the population, sarcopenia has attracted increased attention among geriatricians. In 2010, a definition for sarcopenia was published by the European Working Group on Sarcopenia in Older People (EWGSOP). They defined it as a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life, and death \[[@CR1]\]. In 2018, the working group met again (EWGSOP2) to update the definition of sarcopenia \[[@CR2]\]. In this definition, EWGSOP2 reported that sarcopenia is probable when low muscle strength is detected and sarcopenia diagnosis is confirmed by the presence of low muscle quantity or quality. Sarcopenia is deemed to be severe in cases of low muscle strength, low muscle quantity/quality, and low physical performance. It has a relatively high incidence among the elderly \[[@CR3]\]. Studies have shown \[[@CR4]\] that the incidence of sarcopenia is 5--13% among those 60--70 years of age and 11--50% among those over 80 years of age. Sarcopenia is a progressive and generalized skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability, and mortality \[[@CR2]\]. Consequently, the occurrence of sarcopenia leads to a decline in the quality of life, frailty, and even death among older people \[[@CR5], [@CR6]\].

However, older people often have several chronic diseases. The incidence of comorbidity and the coexistence of two or more diseases \[[@CR7]\] increases with age in older people. The morbidity and mortality of older people with comorbidities are high, and their quality of life is low. Many types of disease are found in older people with comorbidities. For example, chronic obstructive pulmonary disease (COPD) \[[@CR8]\], stroke \[[@CR9]\], Parkinson's disease \[[@CR10]\], and chronic kidney disease \[[@CR11]\] are likely to co-occur with problems such as weakness, malnutrition, and disability. When two or more chronic diseases coexist, the risk of falling and disability in older people is much higher than in those without comorbidity \[[@CR12], [@CR13]\].

The Charlson comorbidity index (CCI) \[[@CR14]\] is currently the most commonly used comorbidity assessment tool. Some studies have been conducted on the association between comorbidity and sarcopenia \[[@CR15]--[@CR17]\]. However, whether the CCI can be used to assess the risk of sarcopenia is unclear. In this study, we reviewed the comorbidity characteristics of chronic diseases in older people potentially suffering from sarcopenia and studied the association between skeletal muscle mass/physical performance and CCI scores.

Methods {#Sec2}
=======

Participants and study design {#Sec3}
-----------------------------

A retrospective analysis was conducted on older people, 65-years-old or older, who were admitted to the Department of Geriatrics, Jinling Hospital, Medical School of Nanjing University between July 2017 and July 2018. Data were collected from the hospital's electronic medical record system and this study was approved by the Ethical Committee of Jinling Hospital. The exclusion criteria were as follows: (1) chest CT examination not performed during hospitalization; (2) long time (\> 1 year) spent in bed; (3) height and weight measurements not taken at admission; (4) patients without comorbidity, and (5) patients with acute sarcopenia---e.g., caused by steroid treatment, neurodegenerative diseases, hip or knee replacement in the previous six months, stroke in the previous six months, or deep vein thrombosis in the previous six months. Only patients who had undergone assessments related to this study were included and patients were enrolled consecutively (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Study flowchart. Patients who met the inclusion and exclusion criteria for the study population. CT: computed tomography

For each patient, the following data were collected: age, sex, smoking status, body mass index (BMI), comorbidity index, length of stay, hospital mortality, chest CT, and laboratory indicators (albumin and hemoglobin).

Sarcopenia {#Sec4}
----------

According to the test for sarcopenia \[[@CR18]\], as developed by the Asian Working Group for Sarcopenia (AWGS), physical performance is generally evaluated on the basis of the individual's gait speed and the established cut-off value for normal gait speed (\< 0.8 m/s, 6 m course). Performance was measured with a stopwatch by one nurse.

In addition, chest CT scans were examined and the diagnosis for sarcopenia was based on an internationally recognized skeletal muscle index (SMI) and sex-specific definition. In order to save extra cost and injury, we chose SMI values derived from the total muscle area (in cm^2^) divided by the square of the height (in m) \[[@CR19], [@CR20]\] at the twelfth thoracic vertebra (T12) level. The diagnosis of sarcopenia was as proposed by Nemec et al. \[[@CR19]\] of Harvard Medical School: SMI values less than 42.6 cm^2^/m^2^ for men and 30.6 cm^2^/m^2^ for women. All data were measured independently by two physicians with CT reading expertise. In this study, all patients underwent chest CT scans without contrast agent. PACS software (SITS 3.6, Philips Healthcare, Guildford, UK) was used to measure the pedicle muscle area (cm^2^) in the chest CT (Fig. [2](#Fig2){ref-type="fig"}a and b). Fig. 2Thoracic SMI with CT of low skeletal muscle mass and normal skeletal muscle mass. Axial computed tomography images of the twelfth thoracic region, with skeletal muscle highlighted in red (40 to 80 Hounsfield units). (**a**) Example of an elderly male patient with a low T12 SMI (\< 42.6 cm^2^/m^2^). (**b**) Example of an elderly male patient with a high T12 SMI (\> 42.6 cm^2^/m^2^). SMI: skeletal muscle index, CT: computed tomography

Charlson comorbidity index (CCI) {#Sec5}
--------------------------------

The CCI is an index used to predict the risks of short-term and long-term patient mortality. It consists of three parts: disease assessment, severity assessment, and scoring. It includes 16 diseases: myocardial infarction, score 1; heart failure, score 1; peripheral arterial obstructive disease, score 1; cerebrovascular disease, score 1; senile dementia, score 1; COPD, score 1; connective tissue disease, score 1; gastroduodenal ulcer, score 1; diabetes, score 1 (involvement of other organs, score 2); chronic kidney disease, score 2; hemiplegia, score 2; leukemia, score 2; malignant lymphoma, score 2; tumor, score 2 (metastasis, score 6); liver disease, score 1 (moderate to severe, score 3); and AIDS, score 6. Age-based scoring starts at the age of 50 years, with a 1 point increase for every 10 years above age 50. The CCI has been used extensively in the medical literature for comorbidity assessment \[[@CR21]\].

Statistical analysis {#Sec6}
--------------------

Measurements taken by the two researchers were averaged for the purposes of outcome analyses. Statistical analyses were performed in SPSS 20.0 (IBM SPSS Statistics for Windows, Armonk, NY, USA). In addition to descriptive statistics, the mean and standard deviation were determined for numeric variables, and the number and percentage were determined for categorical variables. Multivariate analysis of variance was used for comparison of multiple sets of mean vectors. Pearson's and Spearman's correlation analysis and linear regression analysis were used for correlation analysis, and *P* \< 0.05 was considered statistically significant. Meanwhile, PASS 15.0 (Power Analysis and Sample Size) software was used to calculate the statistical power.

Results {#Sec7}
=======

Participant characteristics {#Sec8}
---------------------------

Of the 400 patients who were \> 65 years old, 232 were excluded (Fig. [1](#Fig1){ref-type="fig"}). Consequently, the final study population consisted of 168 patients, of whom 99 (58.93%) were men and 69 (41.07%) were women. Sample size estimation and power analysis revealed a sample size of 168, with α = 0.05 (both sides), achieved 100% power. The mean age was 83.34 ± 7.32 years. The mean duration of stay was 14.19 ± 11.07 days, and the mean BMI was 24.52 ± 3.19 kg/m^2^. In addition, the mean gait speed was 0.69 ± 0.25 m/s. Eighteen (10.71%) patients were smokers. There was no significant difference in age, duration of stay, gait speed, or BMI between men and women (*P* \> 0.05). Detailed demographics and clinical data are presented in Table [1](#Tab1){ref-type="table"}. Among the patients, the incidence of cerebrovascular disease was highest (58.33%), followed by diabetes (38.69%). In addition, 54 (32.14%) patients scored 6 points on the CCI. These measurements are shown in Table [2](#Tab2){ref-type="table"}. Table 1Characteristics of PatientsCharacteristicAll(*n* = 168)Men(*n* = 99)Women(*n* = 69)*P*-value *(Men* vs. *Women)*Age(y)83.34 ± 7.3284.15 ± 7.5482.17 ± 6.880.085Duration of stay(d)14.19 ± 11.0715.51 ± 13.2812.30 ± 6.380.065BMI (kg/m^2^)24.52 ± 3.1924.37 ± 3.4024.75 ± 2.860.44Gait speed(m/s)0.69 ± 0.250.67 ± 0.260.71 ± 0.250.301Smoking, n (%)18 (10.71)15 (15.15)3 (4.35)0.026Age, Duration of stay and *BMI* (mean ± SD)\**P*-value for difference between subgroups with independent sample t test Table 2Comorbidity disease and CCI scoreAll(*n* = 168)Men(*n* = 99)Women(*n* = 69)Comorbidity disease, n (%) MI22 (13.10)13 (13.13)9 (13.04) CHD20 (11.90)17 (17.17)3 (4.35) PAOD6 (3.57)3 (3.03)3 (4.35) CVD98 (58.33)68 (68.69)30 (43.48) SD11 (6.55)2 (2.02)9 (13.04) COPD20 (11.90)11 (11.11)9 (13.04) CTD6 (3.57)0 (0)6 (8.70) GU49 (29.17)31 (31.31)18 (26.09) DM65 (38.69)50 (50.51)15 (21.74) CKD22 (13.10)13 (13.13)9 (13.04) HP2 (1.19)2 (2.02)0 (0) CL0 (0)0 (0)0 (0) ML1 (0.60)1 (1.01)0 (0) tumor49 (29.17)28 (28.28)21 (30.43) LD14 (8.33)11 (11.11)3 (4.35)CCI score, n (%) 411 (6.55)47 533 (19.64)726 654 (32.14)3321 724 (14.29)213 822 (13.10)220 97 (4.17)43 103 (1.79)30 115 (2.98)23 128 (4.76)26 131 (0.60)10*MI* Miocardial infarction, *CHD* Chronic heart failure, *PAOD* Peripheral arterial obstructive disease, *CVD* Cerebral vascular disease, *SD* Senile dementia, *COPD* Chronic obstructive pulmonary disease, *CTD* Connective tissue disease, *GU* Gastroduodenal ulcer, *DM* Diabetes mellitus, *CKD* Chronic kidney disease, *HP* Hemiplegic paralysis, *CL* Chronic leukemia, *ML* malignant lymphadenoma, *LD* Liver disease

Muscle area and SMI in different subgroups {#Sec9}
------------------------------------------

The muscle area of the T12 pedicle was significantly larger in males than in females (*P* \< 0.05), and there was a significant difference in SMI (*P* \< 0.05) between males and females. The muscle area and SMI of patients older than 80 years were lower than those of patients under 80, and this difference was statistically significant (*P* \< 0.05). There was no significant difference in muscle area or SMI between the long-term hospitalized and short-term hospitalized patients (*P* \> 0.05). Similarly, there were no significant differences in muscle area and SMI between the smokers and non-smokers (*P* \> 0.05; Table [3](#Tab3){ref-type="table"}). Table 3Comparison of muscle area and SMI in different subgroupsMuscle area (cm^2^)SMI (cm^2^/m^2^)Gender(n) Male(99)92.92 ± 22.4333.13 ± 7.74 Female(69)73.45 ± 11.0529.73 ± 3.87 *P*-value\< 0.001\< 0.001Age(n)  \> =80 (113)80.69 ± 17.7129.88 ± 5.99  \< 80 (55)93.62 ± 24.3435.54 ± 6.31 *P*-value\< 0.001\< 0.001Duration of stay(n)  \> =30 days(7)82.44 ± 11.5529.09 ± 5.00  \< 30 days(161)85.03 ± 21.2831.84 ± 6.69 *P*-value0.750.284Smoking(n) Yes(18)92.68 ± 24.6633.85 ± 8.64 No(150)83.99 ± 20.3531.48 ± 6.35 *P*-value0.0960.153Muscle area and *SMI* (mean ± SD)

Index differences between the low muscle mass group and normal muscle mass group {#Sec10}
--------------------------------------------------------------------------------

From the SMI values, 121 (72.02%) patients had low muscle mass, including 78 men and 43 women. There were significant differences in the CCI, duration of stay, and serum albumin and hemoglobin levels between the two groups (*P* \< 0.05), but no significant differences in BMI (*P* \> 0.05; Table [4](#Tab4){ref-type="table"}). There was no obvious correlation with sex. Table 4Comparison of indexes between low muscle mass group and normal muscle mass grouplow muscle mass (*n* = 121)normal muscle mass (*n* = 47)AllMale(78)Female(43)AllMale(21)Female(26)CCI7.38 ± 1.98^\*^7.50 ± 1.57^Δ^7.16 ± 2.56^☆^5.13 ± 0.77^\*^5.33 ± 0.80^Δ^4.96 ± 0.72^☆^BMI (kg/m2)24.62 ± 3.2324.22 ± 3.2824.86 ± 2.8524.27 ± 3.1024.90 ± 3.8424.55 ± 2.93Duration of stay(d)15.55 ± 12.33^\*^16.94 ± 14.47^Δ^13.81 ± 6.23^☆^10.70 ± 5.58^\*^10.19 ± 4.55^Δ^9.81 ± 5.93^☆^Alb(g/L)32.64 ± 3.41^\*^32.28 ± 3.75^Δ^33.28 ± 2.58^☆^38.60 ± 2.06^\*^37.97 ± 2.82^Δ^39.10 ± 0.91^☆^Hb(g/L)108.55 ± 13.31^\*^108.68 ± 14.70^Δ^108.30 ± 10.48^☆^132.89 ± 10.80^\*^131.05 ± 13.94^Δ^134.38 ± 7.33^☆^According to thoracic *SMI* level, the subjects were divided into two groups: low muscle mass group and normal muscle mass group. There were significant differences in *CCI*, duration of stay, Alb and Hb between the two groups (^\*^*P* \< 0.05, ^Δ^*P* \< 0.05, ^☆^*P* \< 0.05). There was no significant difference between the sexes (*P* \> 0.05). Alb: albumin, Hb: hemoglobin

The relationship between CCI and SMI/gait speed {#Sec11}
-----------------------------------------------

Linear correlation was used to evaluate the association between CCI and SMI (r = − 0.549, *P* \< 0.05), and between CCI and gait speed (r = − 0.614, *P* \< 0.05) (Fig. [3](#Fig3){ref-type="fig"}). We diagnosed low skeletal muscle mass using the CCI by plotting the receiver operating characteristic curves \[[@CR12]\]. The area under the curve (AUC) was 0.879 (*P* \< 0.05), the maximum Youden index was 0.579, and its corresponding critical value was 6.5 (Fig. [4](#Fig4){ref-type="fig"}). Fig. 3Scatter plot analysis of T12 SMI/gait speed and CCI. The linear correlation method was used to evaluate the association between SMI/gait speed and CCI. SMI: skeletal muscle index, CCI: Charlson comorbidity index Fig. 4ROC curve of low skeletal muscle mass and CCI. ROC curves were constructed to evaluate the sensitivity and 1-specificity of CCI in the diagnosis of low skeletal muscle mass. ROC: receiver operating characteristic, CCI: Charlson comorbidity index

Discussion {#Sec12}
==========

The global population is aging and the association between age and sarcopenia in older persons is well-known. The prevalence of cardiovascular and cerebrovascular diseases, senile dementia, diabetes mellitus, malignant tumors, and other chronic diseases increases with age \[[@CR22]\]. Sarcopenia commonly accompanies aging and numerous diseases. The CCI as the most commonly used tool for comorbidity assessment \[[@CR23]\] and can be used to predict the occurrence of sarcopenia, which may be clinically occult. The study of comorbidity in the elderly can include evaluation of mortality, disability, rehospitalization, length of hospital stay, and post-traumatic mortality, which are used to calculate the CCI scores \[[@CR24]\]. Diagnostic methods include gait speed, dual-energy X-ray, ultrasound, magnetic resonance imaging, and CT \[[@CR3]\]. Physical function is evaluated using gait speed, and CT can accurately distinguish among bone, muscle, fat, and other soft tissues. CT-based SMI scoring is one of the most accurate methods for the diagnosis of sarcopenia \[[@CR1], [@CR25]\]. This method has been used for muscle measurement in patients after liver transplantation \[[@CR26]\] and in those with pancreatic adenocarcinoma \[[@CR27]\]. This measurement of bilateral muscles helps to explain muscle asymmetry associated with scoliosis \[[@CR28]\]. To our knowledge, no prior studies have used the CCI to evaluate the risk of sarcopenia. The purpose of this study was to investigate the association between comorbidity and skeletal muscle mass/physical performance by analyzing CCI scores in older people and to determine the risk of sarcopenia from CCI scores.

Our study showed that there were no significant differences in age, duration of stay or BMI between male and female patients. More males than females were smokers. The most recent research \[[@CR29]\] has shown that malnourished older people have lower levels of myoglobin. That is, malnourished patients are more likely to have sarcopenia. According to the SMI diagnostic criteria of sarcopenia proposed by Harvard Medical School, the subjects were divided into two groups: a normal muscle mass group and a low muscle mass group. There were differences in the CCI score, duration of stay, serum albumin, and hemoglobin between the two groups. The differences in the above indicators were not significantly related to sex. There was no significant difference in BMI, possibly because BMI is not only related to muscle area and height, but also to muscle, fat and other factors \[[@CR30]\]. Through linear correlation analysis, we found a significant negative correlation between SMI/gait speed and the CCI. We analyzed the correlation between the CCI score and age as well as the number and severity of chronic diseases. When multiple diseases coexist, the higher the consumption of nutrients, especially by muscle, the higher the CCI score and the lower the muscle area of older people. In addition, through analysis of the ROC curve and Youden index, we determined that when the CCI score exceeded 6.5, clinicians should be vigilant about determining whether the patient has low skeletal muscle mass. Our results may guide clinical work to assess the risk of sarcopenia in the elderly by using CCI comorbidity assessment tools.

According to the EWGSOP2 update to the original definition of sarcopenia in 2019 \[[@CR3]\], skeletal muscle strength is an important component of diagnostic criteria in sarcopenia. A limitation of our study is the lack of skeletal muscle strength data. This may have led to bias in the diagnosis of sarcopenia. We will address this limitation in our next research. Moreover, the inclusion of only patients with chest CT data available may have led to selection bias and may not be representative of the entire elderly population. CT and the use of a stopwatch is a simple and valid technique that can be used to assess treatment effects, but there are subjective factors involved in investigators' measurements of muscle area and time. Therefore, future studies will need to find objective measurement tools.

In conclusion, in this population, we identified a strong association between the CCI score and SMI/gait speed. We concluded that skeletal muscle mass and physical performance could be assessed using the CCI score. Given the increasing incidence of sarcopenia in the older population, efforts are required to identify new risk factors to predict and prevent the occurrence of sarcopenia.

Conclusions {#Sec13}
===========

We identified an independent association between comorbidity and skeletal muscle mass/physical performance by researching the correlation between the CCI score and SMI/gait speed in individuals aged 65 years and older. Our results suggested an important role of the CCI score in evaluating skeletal muscle mass and physical performance, which may provide important evidence for clinicians to diagnose sarcopenia.

AUC

:   Area under the curve

BMI

:   Body Mass Index

CCI

:   Charlson Comorbidity Index

CHD

:   Chronic heart failure

CKD

:   Chronic kidney disease

CL

:   Chronic leukemia

COPD

:   Chronic obstructive pulmonary disease

CT

:   Computed tomography

CTD

:   Connective tissue disease

CVD

:   Cerebral vascular disease

DM

:   Diabetes mellitus

GU

:   Gastroduodenal ulcer

HP

:   Hemiplegic paralysis

LD

:   Liver disease

MI

:   Miocardial infarction

ML

:   Malignant lymphadenoma

MRI

:   Magnetic resonance imaging

PAOD

:   Peripheral arterial obstructive disease

SMI

:   Skeletal muscle index; SD: Senile dementia

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ge Gong and Wenhui Wan contributed equally to this work.

Not applicable.

Conceived and designed the experiments: GG, JY. Collected the data: GG, YL. Analyzed the data: JY, WHW, XHL, XHZ. Wrote the paper: GG, JY, WHW, XHL. All authors read and approved the final manuscript.

This study was supported primarily by grants from the Health Project Foundation (13BJZ11, 17BJZ17) and a grant from the National Natural Science Foundation of China (No.81701890). The funding body had no role in the design of the study or collection, analysis, and interpretation of data or in writing the manuscript.

On reasonable demand, the corresponding author will supply the datasets used and/or analyzed during the current study.

The study protocol was approved by the Ethical Committee of Jinling Hospital (2017NZGKJ-079) and the Ethical Committee provided consent to access the medical records.

Not applicable.

The authors declare no competing interests.
